Lilly Pre-Approval Spadework Includes Alzheimer’s Blood Test Development, Unbranded DTC Ads

Lilly is supporting development of blood-based tools for early diagnose of Alzheimer's, but the delay of the review for  donanemab will create more distance from Lilly’s direct-to-consumer advertising spotlighting its commitment to Alzheimer’s research.

A Surprise Delay For Launch Preparations • Source: Shutterstock

More from United States

More from North America